TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Monitoring in Primary Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* receiving or seeking medical care at UPMC CMI~* ages 20-65~* GAD7 (anxiety questionnaire) score ≥ 5~* Speaks English speaking~* Capable of understanding and providing consent or assent~Exclusion Criteria:~* under age 20 and older than 65~* GAD7 score \<5~* patients with acute back pain

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Primary care patients (Type: None): Patients ages 20-65 who score 5 or greater on the GAD-7 will be given the SF12, GAD7, medial utilization, and helpfulness questionnaires at 6 month intervals for a 2 year period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Does Thiamine Help Vomiting and Nausea in Pregnancy?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women until 12th week of gestation~* The women visit the ER because of nausea and vomiting~* The women didn't received thiamine yet~Exclusion Criteria:~* Pregnant women over 12th week of gestation~* Women that received thiamine before~* women that allergic to the studied drugs

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. thiamine (Type: ACTIVE_COMPARATOR): Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive thiamine IV
- 2. promethazine (Type: ACTIVE_COMPARATOR): Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive promethazine IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inoperability, or when a patient refuses surgery (i.e. not eligible for (partial-) nephrectomy or RFA);~* Kidney function allows for intervention, as evaluated by treating urologist (taking into account eGFR and renogram);~* Age ≥ 18 years;~* Written informed consent;~* Diagnosis of RCC confirmed by pathology (in case determined after informed consent, patients who are not eligible anymore (no RCC) will be excluded).~Exclusion Criteria:~* Evidence of metastatic disease;~* Exclusion criteria for contrast enhanced MRI scan, according to the protocol of the department of Radiology, UMC Utrecht;~* Patients with one functioning kidney;~* Prior renal surgery (partial nephrectomy);~* Prior radiotherapy on upper abdomen;~* Unsafe to have fiducial marker implantation: i.e. anticoagulant agents use other than acetylsalicyl acid, which cannot be safely stopped/bridged for implantation:~* WHO ≥ 3.~* Chemotherapy \< 3 weeks before treatment;~* Targeted therapy (sunitinib, etc.) ≤ 7 days before treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- ARREST-study (Type: EXPERIMENTAL): SBRT renal cell carcinoma 5 times 7Gy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PRCT: Comparing Two Procedures for Ulno-Carpal Abutment Syndrome.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* persistent ulnar-sided wrist pain of a minimum of 6 months duration despite conservative management~* a positive ulnocarpal stress test~* neutral or positive ulnar variance as measured from a standard posteroanterior radiograph of the wrist~* central TFCC perforation or lunate chondral damage consistent with UAS based on arthroscopic evaluation~* arthroscopically debrided TFCC tear~Exclusion Criteria:~* absence of a TFCC tear or lunate chondral damage~* repairable TFCC tear~* severe ulnocarpal arthrosis~* pre-operative diagnosis of clinically symptomatic scapholunate ligament (SL), lunotriquetral ligament (LT), or distal radioulnar joint (DRUJ) instability~* previous forearm or wrist fracture~* history of inflammatory arthritis~* presence of other wrist pathology~* a requirement for concomitant surgery for an unrelated condition~* skeletal maturity

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Wafer Procedure
- 2 (Type: ACTIVE_COMPARATOR): Ulnar shortening osteotomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EARly Prevention of aTHeroma Progression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women at least 35 years of age~* Mild CAD (nonobstructive coronary atherosclerotic plaques, lumen narrowing \<50%) and CAC score \<300 in at least one segment of proximal or mid-portion of major epicardial coronary arteries~* LDL cholesterol \<130mg/dl~Exclusion Criteria:~* History of stable angina, or acute coronary syndrome~* History of transient ischemic attack, or stroke~* Chronic kidney disease (eGFR\< 60ml/min)~* Diabetes mellitus with microvascular complications or insulin therapy~* Hypertriglyceridemia (triglyceride \>500mg/dl)~* Any statin therapy in the past 4 weeks~* Planned cardiac surgery or planned major non-cardiac surgery within 6 months.~* Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).~* A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.~* Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.~* Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST \> 3 times upper limit of normal).~* History of adult asthma manifested by bronchospasm in the past 6 months, or currently taking regular anti-asthmatic medication(s).~* Unwillingness or inability to comply with the procedures described in this protocol.~* Positive pregnancy test (all female subjects of childbearing potential must have a urine ß-human chorionic gonadotropin(hCG) pregnancy test performed at Screening and/ or within 7 days prior to randomization) or is known to be pregnant or lactating.~* Hypersensitivity to Crestor~* Skeletal muscle disease~* Combination use with cyclosporine~* Galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption~* Combination use of protease inhibitor

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Therapy (Type: ACTIVE_COMPARATOR): Risk factor control Diet Exercise
- Rosuvastatin therapy (Type: EXPERIMENTAL): Risk factor control Rosuvastatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Early Enteral vs. Parenteral Nutrition on Risk of Gastric-Content Aspiration in Patients Requiring Mechanical Ventilation and Catecholamines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Invasive mechanical ventilation expected to be required more than 48 hours~* Nutrition started within 24 hours after initiation of endotracheal mechanical ventilation~* Treatment with vasoactive drug administered via a central venous catheter~* Age over 18 years~* Signed information~Exclusion Criteria:~* Abdominal surgery within 1 month before inclusion~* History of esophageal, gastric, duodenal or pancreatic surgery~* Bleeding from the esophagus, stomach or bowel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Parenteral nutrition (Type: ACTIVE_COMPARATOR): Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level \< 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
- Enteral nutrition (Type: ACTIVE_COMPARATOR): Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The pathological examination of renal biopsy was consistent with the early idiopathic membranous nephropathy~2. Meeting one of the following three condition：~   * Urine protein quantitation \>4g/d,or 50% higher than baseline,RASS blocker treat for 6 months without trend of decrease ②Serious or disabling complications related to nephrotic syndrome ③In the 6-12 months after diagnosis of idiopathic membranous nephropathy, serum creatinine increased by more than 30%, while eGFR eGFR≥25ml/min/1.73m2.And excludeing other causes of renal dysfunction~Exclusion Criteria:~1. Secondary membranous nephropathy~2. Serious complications~3. Considering the effect of cyclophosphamide on the of function of sex gland，all patients with childbearing age or fertility requirement cannot participate in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group prednisone (Type: EXPERIMENTAL): Prednisone was taken 1mg/kg/d(maximum 60mg/d)for 8 weeks to start.Then decreased 5mg every 2 weeks; When reduced to 40mg,reduced 5mg every 4 weeks. When reduced to 20mg, reduced 2.5mg every 8 weeks until the end.
- Group MP and CTX (Type: ACTIVE_COMPARATOR): The first month,Methylprednisolone(MP) was injected for 3 days(weight \>60kg,500mg/d;\<60 kg,300mg/d),and 0.4mg/kg/d for 27 day.The second month,Cyclophosphamide(CTX) orally was 100mg/d for 1 month.And this regimen is repeated for six months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Confirmed by histopathological or cytological examination; The criteria for resectability is met; Has at least one evaluable lesion according to the RECIST 1.1 standard and has not received local treatment;~Exclusion Criteria:~Patients who previously received anti-programmed death receptor-1 (PD-1) antibody, anti-programmed death ligand-1 (PD-L1) antibody, anti-programmed death ligand-2 (PD-L2) antibody or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibodies, including those who have participated in a JS001 clinical study;~Patients with a history of gastroesophageal varices or active cardia ulcers associated with a high risk of bleeding; Patients who have upper gastrointestinal hemorrhage within 1 year; Patients known to have fibrous layer HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC; Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.
- Group B (Toripalimab, Lenvatinib) (Type: EXPERIMENTAL): During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W and lenvatinib for up to 48 weeks.
- Group C (Toripalimab, Lenvatinib) (Type: ACTIVE_COMPARATOR): During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Generally healthy female \> 40 years of age with a body mass index (BMI) ≤ 40;~2. Has undergone menopause defined as any of the following:~   At least 12 months of spontaneous amenorrhea; or At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels \> 40 mIU/mL; or At least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy);~3. Experience a minimum of 7 moderate to severe hot flushes per day or 50 moderate to severe hot flushes per week~Exclusion Criteria:~1. Resting systolic blood pressure (SBP) \<110 mmHg, resting diastolic blood pressure (DBP) \<50 mm Hg, or a resting heart rate (HR) \<60 beats per minute while awake;~2. Subjects with pre-existing orthostatic hypotension at Screening;~3. Use of oral estrogen-, progestin-, androgen-, or selective estrogen receptor modifier (SERM) -containing drug products within 8 weeks prior to Screening; use of transdermal hormone products within 8 weeks prior to Screening; use of vaginal hormone products (rings, creams, gels) within 4 weeks prior to Screening; use of intrauterine progestins within 8 weeks prior to Screening; use of progestin implants or estrogen injectables within 3 months prior to Screening; use of estrogen pellet or progestin injectables within 6 months prior to Screening;~4. History of daily usage (at least 28 days/month) of either of the following during the month prior to initiation of Screening: Antihypertensives or Prophylactic antimigraine medications

- Gender: FEMALE
- Minimum Age: 41 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AR08 0.5 mg/day (Type: EXPERIMENTAL): AR08 QD oral dosing for 14 weeks
- AR08 1.0 mg/day (Type: EXPERIMENTAL): AR08 QD oral dosing for 14 weeks
- AR08 2.0 mg/day (Type: EXPERIMENTAL): AR08 QD oral dosing for 14 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo QD oral dosing for 14 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female between 18 and 70 years old;~* Patients with histologic proved metastatic breast cancer;~* Pleural effusion with the volume of more than 1000ml, as documented by CT, X ray or ultrasound;~* There are no other diseases which cause the elevation of IL-6 or IL-8, such as cirrhosis of liver, anaphylactoid purpura, acute pancreatitis;~* With at least one measurable disease according to RECIST criteria,~* Normal laboratory results:ANC≥2.0×109/L,Hb≥80g/L,plt≥100×109/L,TB\<UNL (\<1.5 x UNL in patients with liver mets),ALT/AST\< 1.5 x UNL (\<2.5x UNL in patients with liver mets),AKP\<5 x UNL(except bone mets),Cr\<UNL;~* Normal functions with heart, liver,renal and bone marrow;~* Got ICF before enrollment;~* Life expectancy more than 12 weeks.~Exclusion Criteria:~* Pregnant or breast-feeding women or positive serum pregnancy test;~* Uncontrolled brain metastases;~* No recovery from previous radiation or accepted radiation within 4 weeks before enrollment;~* Participation in any investigational drug study within 4 weeks preceding treatment start;~* Concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin;~* Serious uncontrolled intercurrent infections;~* Poor compliance.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- pleural effusion (Type: None): patients with pleural effusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women, aged 18-65 years old~* Prior endoscopic confirmation of UC:~Mildly to moderately active UC with Simple Clinical Colitis Activity Index (SCCAI) activity index \>4-9~* Failing standard therapy with:~stable doses of 5-ASA \>2 weeks; thiopurines \>3 months; or is steroid dependent at a dose \<20mg/d; (inability to taper off steroid for longer than 1 week)~* Stable medications dose for at least 2 weeks prior to screening and upon entry into trial~* Ability to understand and willingness to sign informed consent document~Exclusion Criteria:~* Diagnosis of Crohn's disease, indeterminate colitis, or proctitis alone~* Severe or fulminate colitis~* Women who are pregnant or nursing~* Patients who are unable to give informed consent~* Patients who are unable or unwilling to undergo colonoscopy~* Patients who have previously undergone FMT~* Patients who have a confirmed malignancy or cancer~* Patients who are immunocompromised~* Treatment within last 12 weeks with cyclosporine, tacrolimus, infliximab, adalimumab, certolizumab, natalizumab, thalidomide~* Antibiotic use within 2-months of start date~* Participation in a clinical trial in the preceding 30 days or simultaneously during this trial~* Probiotic use within 30 days of start date~* Rectal therapy within 14 days of start date~* Decompensated cirrhosis~* Congenital or acquired immunodeficiencies~* Other comorbidities including:~Diabetes mellitus, cancer, systemic lupus, must be able to tolerate conscious sedation with colonoscopy~* Chronic kidney disease as defined by a GFR \<60mL/min/1.73m2 (40)~* History of rheumatic heart disease, endocarditis, or valvular disease due to risk of bacteremia.~* Steroid \>20mg/day~* Positive screening and confirmatory tests for HIV 1 \& 2, Hepatitis A, B, \& C, and Syphilis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- fecal microbiota transplantation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness Study of the International Child Development Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* SDQ \>/= 9, subjective treatment need~Exclusion Criteria:~* Already in treatment

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- ICDP (Type: EXPERIMENTAL): International Child Development Program
- Treatment as usual (Type: ACTIVE_COMPARATOR): Treatment as usual

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues